fashion -WSS

fashion

author：explore 2025-09-06 01:59:50 - browse：1

parts of a dna helix fades while a segment stays solid — Adobe

Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called Quotient Therapeutics that will have offices in Massachusetts and the United Kingdom.

Quotient, which was founded last year and had operated in stealth mode, wants to develop drugs that target illnesses caused by genetic changes that occur as people age. Those conditions include immune diseases, cancers, neurodegenerative illnesses, and cardiometabolic disorders, such as heart attacks, strokes and diabetes.

With an initial of $50 million from the venture firm Flagship Pioneering, Quotient will be located in Cambridge, Mass., and Cambridge, England. Most of the academic co-founders work in the UK city. Quotient is the first Flagship-backed biotech that will be based in both countries.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： FDA struggles to regulate food additives, sometimes for decades

WSS

The surgeon had a dilemma only a Nazi medical text could resolve

FDA clears AI tool for detecting skin cancer

Senate committee scrutinizes Medicare Advantage brokers

Humana cuts profit projections as Medicare Advantage costs soar

Research misconduct: Proposed new rules face resistance

Research misconduct: Proposed new rules face resistance

Wikipedia

fashion

entertainment

23andMe had bad news about my health. I wish a person had delivered it

NIH director takes cautious approach to Biden drug pricing priority

Moonlake's readout produced a cash windfall. Risks remain

FDA clears AI tool for detecting skin cancer

As demand for Covid shots wanes, Moderna seeks its next success

Solve the antibiotic resistance crisis with preventive drugs

United colonoscopy coverage change 'may cost lives,' doctors say

Think you might have Covid

At least 13 dead in Texas as scorching temps continue

STAT Summit: GSK CEO on pharma giant's new direction

focus

Will Ozempic

The surgeon had a dilemma only a Nazi medical text could resolve

How digital therapeutics firms are pivoting after Pear's bankruptcy

FDA warns J&J's Abiomed: We will regulate your software

The explosion of genetic testing requires a new approach

STAT Summit: Michael J. Fox on progress in Parkinson's research

knowledge

Wikipedia

focus

knowledge